RESEARCH

Vascular system & stroke

Ayodele O, Cabral HJ, McManus D, Jick S. The risk of venous thromboembolism (VTE) in men with benign prostatic hyperplasia treated with 5-alpha reductase inhibitors (5ARIs). Clin Epidemiol. 2021 Aug 3. doi:10.2147/CLEP.S317019 | PubMed | PMC full text

Choi BK, Cheon K, Cho BH, Jung JW, Lee KY. Cerebral venous sinus thrombosis associated with dutasteride use. Yonsei Med J. 2020 Jun. doi:10.3349/ymj.2020.61.6.553 | PubMed | PMC full text

Chou CH, Lin CL, Lin MC, Sung FC, Kao CH. 5α-reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. J Endocrinol Invest. 2015 Jul;38(7):799-805. doi:10.1007/s40618-015-0263-1 | PubMed

Kang DW, Jeong HG, Kim HR, et al. Finasteride induced cerebral venous thrombosis. Journal of the Korean Neurological Association. 2015;33(3):238-240. PDF at ResearchGate

Kuno T, Uchida Y, Usami T, et al. A young male of [sic] hemorrhagic cerebral infarction associated with finasteride and minoxidil. Nosotchu. 2019 Nov;42(4). Japanese. doi:10.3995/jstroke.10722 • ResearchGate • Automated translation to English (unofficial)

Loke YK, Ho R, Smith M, et al. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor – dutasteride. J Clin Pharm Ther. 2013 Oct;38(5):405-15. doi:10.1111/jcpt.12080 | PubMed

Tsuji Y, Nakayama T, Bono K, Kitamura M, Imafuku I. [Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan]. Rinsho Shinkeigaku. 2014;54(5):423-8. Japanese. doi:10.5692/clinicalneurol.54.423 | PubMed